Intraoperative Carcinoid Syndrome During Small-Bowel NET Surgery: Description, Prevalence and Risk Factors. Abstract #1685

Introduction: Few studies on intraoperative carcinoid syndrome (ioCS) are available.
Aim(s): Aims were to describe, define ioCS diagnosis criteria and evaluate ioCS risk factors.
Materials and methods: We retrospectively analyzed patients operated for small-bowel (SB) NET in our ENETS excellence center (2007-2015) receiving preoperative continuous octreotide (40 or 80 µg.h-1 according to the presence of liver metastases or prior CS). ioCS was defined as highly-probable (rapid arterial blood pressure changes ≥ 40% without surgical/anesthetic reasons and regressive ≥ 20% after octreotide injection), probable (one criteria missing) or suspected (octreotide injection for manifestation not meeting criteria of highly-probable and probable ioCS).
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Myrtille Fouché

To read results and conclusion, please login ...

Further abstracts you may be interested in

#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols
#800 Somatostatin Analogues for Carcinoid Syndrome
Introduction: Carcinoid syndrome is a significant clinical problem in neuroendocrine tumors (NETs). Somatostatin analogues (SSA) have been the mainstay management for carcinoid syndrome.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: LJ Guo
Authors: Guo L, Tang C, ...
#1064 Development of Effective Prophylaxis Against Intraoperative Carcinoid Crisis
Introduction: Patients with foregut and midgut neuroendocrine tumors (NETs) can experience life-threatening carcinoid crises during anesthesia. The prophylactic use of a pre-, intra- and post-operative high dose continuous octreotide infusion was evaluated for its ability to prevent carcinoid crises during cytoreductive surgeries.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Eugene Woltering
Keywords: carcinoid crisis
#1296 The Application of Octreotide in a SINET Patient with Carcinoid Syndrome, Carcinoid Heart Disease and Carcinoid Crisis: A Case Report
Introduction: In Chinese population, small intestinal neuroendocrine tumor (SINET) only accounts for 2.2% of gastroenteropancreatic NET, while carcinoid syndrome, carcinoid heart disease (CHD) and carcinoid crisis are rarer.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Luohai Chen
Authors: Chen L, Zhang Y, Chen M, Chen J, ...